H.C. Wainwright analyst Arthur He downgraded Prime Medicine (PRME) to Neutral from Buy without a price target The company decided to discontinue the development of PM359 for the treatment of chronic granulomatous disease as well as the X-linked CGD program, while focusing on its in vivo liver franchise including PM577 for Wilson’s Disease and recently unveiled alpha-1 antitrypsin deficiency program, the analyst tells investors in a research note. The firm is surprised by Prime’s decision and now sees financial and legal uncertainties as well as a lack of catalysts for the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine price target lowered to $6 from $10 at Citizens JMP
- Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty
- Prime Medicine downgraded to Neutral from Overweight at JPMorgan
- Prime Medicine price target lowered to $12 from $16 at Chardan
- Prime Medicine Appoints New CEO Amid Restructuring